Korro Bio, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Korro Bio is in Stage 4, the downtrend phase, now in week 2 (since Oct 15, 2026). It closed at $12.05, 70.5% below its 52-week high and above its 200-day average, which is rising.

$12.05

+29.71% today

$177M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is KRRO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 26w

S4 31w

S1 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 6w → S4 7w → S1 2w → S2 26w → S3 6w → S4 8w → S1 3w → S4 4w → S1 5w → S2 5w → S3 1w → S4 31w → S1 7w → S2 8w → S3 4w → S4 8w → S1 16w → S4 9w → S1 1w → S2 5w → S3 3w → S4 1w current

Total tracked: 164 weeks across 22 stage runs.

KRRO among Biotechnology428th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…428	KRROKorro Bio, Inc.	Stage 4 · wk 2	15	+22.6%

vs 52W High

-70.5%

$5.28 lo$40.91 hi

70.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

2.1%

200 DMA: $11.80 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

3.04x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+22.6%

+13.3%

-11.4%

YTD

+49.7%

-70.9%

Scan Membership

Breakout Watch

Latest: 2024-11-27

5 appearances in last 60 days. First seen: 2020-07-20.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 3.04x

2026-10-21S4

Wk 1 · Vol 0.62x

2026-10-20S4

Wk 1 · Vol 1.53x

2026-10-19S4

Wk 1 · Vol 0.88x

2026-10-16S4

Wk 1 · Vol 0.84x

2026-10-15S43→4

Wk 1 · Vol 2.98x

2026-10-14S3

Wk 4 · Vol 1.48x

2026-10-13S3

Wk 4 · Vol 1.85x

2026-10-12S3

Wk 4 · Vol 0.99x

2026-10-09S3

Wk 3 · Vol 0.94x

2026-10-08S3

Wk 3 · Vol 1.18x

2026-10-07S3

Wk 3 · Vol 1.11x

Moving averages & range

50 DMA

$11.41

200 DMA

$11.80

52W High

$40.91

52W Low

$5.28

5D Low

$8.49

Resistance levels (recent highs)

20d High

$12.05

60d High

$14.07

120d High

$14.72

250d High

$40.91

Next resistance

+16.8%

to 60d High

ROE

-97.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.7

Korro Bio: quick answers

What stage is Korro Bio in?

As of Oct 22, 2026, Korro Bio (KRRO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Korro Bio in an uptrend?

No. Korro Bio is in a Stage 4 downtrend. It trades 2.1% above its 200-day average, which is rising.

How far is Korro Bio from its 52-week high?

Korro Bio closed at $12.05 on Oct 22, 2026, 70.5% below its 52-week high of $40.91. Its 52-week low is $5.28.

How has Korro Bio performed over the past year?

As of Oct 22, 2026, Korro Bio is down 70.9% over the past year and up 49.7% so far in 2026.

Which sector and industry is Korro Bio in?

Korro Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.